HC Wainwright Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price objective increased by HC Wainwright from $82.00 to $95.00 in a research note issued to investors on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical’s Q4 2024 earnings at ($1.37) EPS, FY2024 earnings at ($6.26) EPS, Q1 2025 earnings at ($1.20) EPS, Q2 2025 earnings at ($1.11) EPS, Q3 2025 earnings at ($1.03) EPS, Q4 2025 earnings at ($0.96) EPS, FY2025 earnings at ($4.29) EPS, FY2026 earnings at ($1.18) EPS, FY2027 earnings at $3.46 EPS and FY2028 earnings at $9.33 EPS.

RARE has been the subject of a number of other research reports. Wedbush boosted their price objective on shares of Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the company a “neutral” rating in a research report on Friday, August 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $116.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, October 22nd. TD Cowen boosted their price objective on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Canaccord Genuity Group reaffirmed a “buy” rating and set a $111.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, July 23rd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Thursday, September 26th. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $86.69.

Ultragenyx Pharmaceutical Stock Performance

Shares of Ultragenyx Pharmaceutical stock opened at $50.36 on Wednesday. The firm has a market cap of $4.65 billion, a PE ratio of -7.78 and a beta of 0.58. The firm’s 50-day simple moving average is $55.06 and its 200-day simple moving average is $48.19. Ultragenyx Pharmaceutical has a 1 year low of $34.06 and a 1 year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.05. The business had revenue of $139.49 million for the quarter, compared to analyst estimates of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 197.73%. The company’s revenue for the quarter was up 42.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($2.23) EPS. On average, equities analysts predict that Ultragenyx Pharmaceutical will post -6.29 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Emil D. Kakkis sold 20,000 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total value of $1,117,000.00. Following the completion of the transaction, the chief executive officer now directly owns 2,223,985 shares in the company, valued at $124,209,562.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CEO Emil D. Kakkis sold 20,000 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total value of $1,117,000.00. Following the completion of the transaction, the chief executive officer now directly owns 2,223,985 shares in the company, valued at $124,209,562.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Howard Horn sold 7,465 shares of the stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total transaction of $393,853.40. Following the completion of the transaction, the chief financial officer now owns 92,301 shares of the company’s stock, valued at $4,869,800.76. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 27,556 shares of company stock worth $1,515,967. Insiders own 5.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in Ultragenyx Pharmaceutical by 513.8% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 507,095 shares of the biopharmaceutical company’s stock valued at $23,677,000 after purchasing an additional 424,476 shares during the last quarter. Clearbridge Investments LLC lifted its stake in Ultragenyx Pharmaceutical by 0.7% during the first quarter. Clearbridge Investments LLC now owns 2,400,854 shares of the biopharmaceutical company’s stock valued at $112,096,000 after purchasing an additional 17,362 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Ultragenyx Pharmaceutical by 3.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,568,873 shares of the biopharmaceutical company’s stock valued at $166,632,000 after purchasing an additional 120,175 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in Ultragenyx Pharmaceutical during the first quarter valued at approximately $1,074,000. Finally, Vanguard Group Inc. lifted its stake in Ultragenyx Pharmaceutical by 0.3% during the first quarter. Vanguard Group Inc. now owns 8,700,007 shares of the biopharmaceutical company’s stock valued at $406,203,000 after purchasing an additional 26,575 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.